Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAP-144 · 2 trials · 2 indications
Comparison of both the treatment groups was done by assessing the suppressive effect on serum E2 concentration maintained at menopausal level (=\<30pg/mL). Suppression rate was calculated as proportion of participants maintained at menopausal level.
Comparison of the proportion of patients maintained at castration level (≤100 ng/dL)
| Arm | Type | Description |
|---|---|---|
| TAP-144-SR(6M) | EXPERIMENTAL | TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks. |
| TAP-144-SR(3M) | ACTIVE_COMPARATOR | TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks. |
| Name | Type | Description |
|---|---|---|
| TAP-144-SR(6M) | DRUG | - |
| TAP-144-SR(3M) | DRUG | - |
Inclusion Criteria: 1. The participant has histopathologically-confirmed primary breast cancer in Japanese. 2. The participant is aged 20 years or older when informed consent is obtained 3. The participant has estrogen receptor (ER)-positive tumor cells and/or progesterone receptor (PgR)-positive p...
TAP-144 is an investigational small molecule being studied for the treatment of premenopausal breast cancer and prostate cancer. It is being developed by Takeda Pharmaceutical Company Limited (TAK) and is currently in Phase 3 clinical development.
TAP-144 is a small molecule, but its specific molecular target has not been disclosed in available information. It is being studied in oncology indications, specifically premenopausal breast cancer and prostate cancer.
TAP-144 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The drug is currently in Phase 3 clinical trials for premenopausal breast cancer and prostate cancer.
TAP-144 is in Phase 3 clinical development. It has completed one Phase 3 trial in prostate cancer and one Phase 3 trial in premenopausal breast cancer, both conducted in Japan.
TAP-144 has been studied in two completed Phase 3 trials: NCT01546623 in prostate cancer patients previously treated with hormonal therapy (enrollment 160) and NCT01546649 in postoperative, hormone therapy-naive patients with premenopausal breast cancer (enrollment 167). Both trials were conducted in Japan.
TAP-144 is also known as TAP-144-SR, as referenced in the clinical trial titles. The trials evaluated TAP-144-SR(6M), a formulation of the drug, in prostate cancer and premenopausal breast cancer patients.